The REMAP-CAP study has shown that the use of immunosuppressive drugs in patients with COVID-19 when first admitted to ICU reduces mortality by one-quarter and can reduce ICU stays by one week.

Dr Babu Muthuswamy, Consultant Intensivist at Aneurin Bevan University Health Board presents a new tutorial exploring the evidence base of these findings, eligibility criteria and the clinical considerations such as dosing regime and side effects.